ArchiveJuly 2016

Cancer Risk with Mitoxantrone

Buttmann M, Seuffert L, Mäder U, Toyka KV. Malignancies after mitoxantrone for multiple sclerosis: A retrospective cohort study. Neurology. 2016 Jun 7;86(23):2203-7. OBJECTIVE:To assess the therapy-related risk of malignancies in mitoxantrone-treated patients with multiple sclerosis.METHODS:This retrospective observational cohort study included all mitoxantrone-treated patients with multiple...

Mapping the Brain

Glasser MF, Coalson TS, Robinson EC, Hacker CD, Harwell J, Yacoub E, Ugurbil K, Andersson J, Beckmann CF, Jenkinson M, Smith SM, Van Essen DC. A multi-modal parcellation of human cerebral cortex. Nature. 2016 Jul 20. doi: 10.1038/nature18933. [Epub ahead of print] Understanding the amazingly complex human cerebral cortex requires a map (or parcellation) of its major subdivisions, known as...

Assessing Animal Data is it Pants or Not?

EAE #MSresearch #MSBlog This week ProfB presented to a group of students on EAE and left his slides on the blog. The students also had a session on experimental design. Central to this is how to analyse data. Someone commented on this. I must admit we are all pretty bad a statistics, but it seems that some EAEologists are worse than others Someone I know had a grant sent back...

Choosing Drugs

Select item 27366235 Quantitative analysis of multiple sclerosis patients’ preferences for drug treatment: a best-worst scaling study. Lynd LD, Traboulsee A, Marra CA, Mittmann N, Evans C, Li KH, Carter M, Hategekimana C.Ther Adv Neurol Disord. 2016 Jul;9(4):287-96. doi: 10.1177/1756285616648060. Epub 2016 May 15. Lynd LD, Traboulsee A, Marra CA, Mittmann N, Evans C, Li KH, Carter M...

Occurance of Unrinary Problems

Zecca C, Riccitelli GC, Disanto G, Singh A, Digesu GA, Panicari L, Puccini F, Mattioli M, Tubaro A, Gobbi C. [Epub]Urinary incontinence in multiple sclerosis: prevalence, severity and impact on patients’ quality of life. EUR J NEUROL. 2016 DOI: 10.1111/ENE.13010. BACKGROUND AND PURPOSE:Lower urinary tract symptoms (LUTS) including frequent urination, nocturia and urge urinary...

The Trajectory of MS..Is an MS nurse the best MS DMT?

Hum S, Lapierre Y, Scott SC, Duquette P, Mayo NE.Trajectory of MS disease course for men and women over three eras.Mult Scler. 2016 Jun 30. pii: 1352458516655478. [Epub ahead of print] Background: Heterogeneity in disease course exists within multiple sclerosis (MS) subtypes. Objective: The objective was to estimate disease course heterogeneity over three distinct onset periods (pre-1995...

A day in the life of the B cell follicle

J Neuropathol Exp Neurol. 2016 Jul 13. pii: nlw063. [Epub ahead of print] RORγt Expression and Lymphoid Neogenesis in the Brain of Patients with Secondary Progressive Multiple Sclerosis. Serafini B, Rosicarelli B, Veroni C, Zhou L, Reali C, Aloisi F. Abstract Ectopic B-cell follicle-like structures (ELS) are found in the meninges of patients with secondary progressive multiple sclerosis (SPMS)...

Cladribine for MS – Merck back on the road to licensing

So now it’s official: Merck’s submission to the EMA for marketing authorisation of their oral Cladribine preparation (Cladribine tablets) for treatment of people with relapsing MS has been accepted. The EMA may now take approximately 15 months until a decision is out. Many of you are aware we have been working hard during the ‘gap years’ Merck took from Cladribine after...

Is IMPACT coming our way-Merck back at the EMA

#MSResearch #MSBlog Cladribine is back on the table One of the biggest drivers for improving/messing up the University System has been the Research Asssessment Excersises, now called the REF (Research Excellence Framework). These done every 5-7years are supposed to be a mechanism to increase the standard of academics within the university system. In some cases this means bullying and...

Translate

Categories

Recent Posts

Recent Comments

Archives